Tags

Type your tag names separated by a space and hit enter

5-alpha-reductase inhibitors (5ARI) for benign prostatic hyperplasia

Evidence Summaries

Level of Evidence = A

Finasteride and dutasteride reduce prostate volume, increase urinary flow and improve symptoms in benign prostatic hyperplasia.

A Cochrane review 1 on finasteride for benign prostatic hyperplasia included 23 studies with a total of 21,945 subjects. Finasteride consistently improved urinary symptom scores more than placebo in trials of > 1 year duration (4 studies), and significantly lowered the risk of BPH progression (acute urinary retention, risk of surgical intervention, ≥ 4 point increase in the AUASI/IPSS). There was an increased risk of ejaculation disorder, impotence, and lowered libido for finasteride versus placebo.

A systematic review 2 including 11 studies with a total of 13,822 subjects was abstracted in DARE. Reductions in prostate volume, increases in urinary flow rates and improvements in symptoms compared with placebo have been observed in trial of up to 4 years´ duration and in noncomparative extensions (up to 6 years). Results from the PLESS trial show finasteride to significantly reduce the risk of acute urinary retention and requirement for surgical intervention. Similar efficacy has been reported with the novel 5-ARI dutasteride which inhibits both subtype I and subtype II 5-alpha-reductase.

References

1. Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev 2010;(10):CD006015.  [PMID:20927745]

2. Wilde MI, Goa KL. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. Drugs 1999 Apr;57(4):557-81.  [PMID:10235693]

3. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 Sep;60(3):434-41.  [PMID:12350480]

4. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004 Oct;46(4):488-94; discussion 495.  [PMID:15363566]


Copyright © 2017 Duodecim Medical Publications Limited.
5-alpha-reductase inhibitors (5ARI) for benign prostatic hyperplasia is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.

Citation

"5-alpha-reductase Inhibitors (5ARI) for Benign Prostatic Hyperplasia." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455245/all/5_alpha_reductase_inhibitors__5ARI__for_benign_prostatic_hyperplasia.
5-alpha-reductase inhibitors (5ARI) for benign prostatic hyperplasia. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455245/all/5_alpha_reductase_inhibitors__5ARI__for_benign_prostatic_hyperplasia. Accessed August 20, 2019.
5-alpha-reductase inhibitors (5ARI) for benign prostatic hyperplasia. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/455245/all/5_alpha_reductase_inhibitors__5ARI__for_benign_prostatic_hyperplasia
5-alpha-reductase Inhibitors (5ARI) for Benign Prostatic Hyperplasia [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 August 20]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455245/all/5_alpha_reductase_inhibitors__5ARI__for_benign_prostatic_hyperplasia.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - 5-alpha-reductase inhibitors (5ARI) for benign prostatic hyperplasia ID - 455245 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455245/all/5_alpha_reductase_inhibitors__5ARI__for_benign_prostatic_hyperplasia PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -